<DOC>
	<DOCNO>NCT00171821</DOCNO>
	<brief_summary>This study use single arm , multi-center , open-label trial design . The study ass efficacy safety 52 week treatment deferasirox ( ICL670 ) patient evidence transfusion induce iron overload .</brief_summary>
	<brief_title>A Study Assessing Efficacy Safety Deferasirox Patients With Transfusion-dependent Iron Overload</brief_title>
	<detailed_description />
	<mesh_term>Iron Overload</mesh_term>
	<mesh_term>Deferasirox</mesh_term>
	<criteria>Patients present transfusiondependent anemia ( independent underlie condition ) transfusional iron overload show serum ferritin level ≥ 1000 ng/ml Patients either gender age ≥ 2 year Female patient reach menarche sexually active must use effective method contraception , must undergo clinically document total hysterectomy and/or ovariectomy , tubal ligation . Additional Inclusion Criteria Adult Patients : Written inform consent patient Additional Inclusion Criteria Pediatric Patients : The definition term `` pediatric '' accordance local legislation . Parents legal guardian fully inform investigator requirement study . The pediatric patient inform accord capability language term able understand . Written inform consent obtain parent legal guardian patient 's behalf accordance national legislation . If capable , patient also personally sign write informed assent . Nontransfusional hemosiderosis Patients clinical evidence support need intensive chelation , base investigator 's judgment Patients mean level alanine aminotransferase ( ALT ) &gt; 300 U/l Patients uncontrolled systemic hypertension Patients serum creatinine upper limit normal ( ULN ) Significant proteinuria indicate urinary protein/creatinine ratio &gt; 0.5 ( mg/mg ) secondvoiding urine sample take visit 1 2 . A third sample take patient one ratio &gt; 0.5 ( mg/mg ) one ≤ 0.5 ( mg/mg ) patient urinary protein/creatinine ratio &gt; 0.5 ( mg/mg ) two three determination also exclude . History nephrotic syndrome Patients 3rd atrioventricular ( AV ) block , clinically relevant QT interval prolongation well patient require treatment digoxin similar compound drug may induce prolongation QT interval Patients previous history clinically relevant ocular toxicity relate iron chelation Systemic disease ( cardiovascular , renal , hepatic , etc . ) would prevent patient undergo study treatment Patients psychiatric addictive disorder prevent give inform consent undergo study treatment Pregnant breast feeding patient Patients treated systemic investigational drug within past 4 week topical investigational drug within past 7 day Any surgical medical condition might significantly alter absorption , distribution , metabolism excretion drug . The investigator guide evidence following : history inflammatory bowel syndrome , gastritis , ulcer , gastrointestinal rectal bleeding ; history major gastrointestinal tract surgery gastrectomy , gastroenterostomy , bowel resection ; history pancreatic injury pancreatitis ; indication impair pancreatic function/injury indicate abnormal lipase amylase ; history presence impair renal function indicate creatinine blood urea nitrogen ( BUN ) value equal ULN ; history urinary obstruction difficulty void . History noncompliance medical regimen patient consider potentially unreliable and/or cooperative History drug alcohol abuse within 12 month prior dose evidence abuse indicate laboratory assay conduct runin period Patients positive test HIV Life expectancy &lt; 1 year Exclusion Criteria Pediatric Patients : Patient body weight prevents use small tablet strength ( i.e . 125 mg ) proper dose Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Thalassemia</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>MDS</keyword>
	<keyword>Sickle cell</keyword>
	<keyword>Diamond-Blackfan anemia</keyword>
	<keyword>Transfusion</keyword>
	<keyword>Anemia</keyword>
	<keyword>Fanconi</keyword>
	<keyword>Chelation</keyword>
	<keyword>Deferasirox</keyword>
</DOC>